David Venables
Chief Executive Officer at Synpromics Ltd.
Profile
David C.
Venables is currently the Chief Executive Officer at Synpromics Ltd.
and the Chief Executive Officer & Director at Laverock Therapeutics Ltd.
Previously, he held positions such as Chief Executive Officer, Director & MD at Anatara Lifesciences Ltd.
from 2014 to 2015, Non-Executive Director at Ark Therapeutics Group Plc from 2012 to 2015, Operations Director at Q-One Biotech Ltd., Head-Process Development at Medeva Plc, and Chief Operating Officer at Intercell USA, Inc. He obtained his doctorate degree from the University of Surrey in 1993.
David Venables active positions
Companies | Position | Start |
---|---|---|
Synpromics Ltd.
Synpromics Ltd. Chemicals: SpecialtyProcess Industries Synpromics Ltd. develops and commercializes synthetic promoters to control gene expressions and regulations. The firm is active in cell and gene therapy, biologics bioprocessing, and industrial biotechnology. The company was founded by Michael L. Robert in 2010 and is headquartered in Edinburgh, the United Kingdom. | Chief Executive Officer | - |
Laverock Therapeutics Ltd.
Laverock Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables. | Chief Executive Officer | 2021-07-31 |
Former positions of David Venables
Companies | Position | End |
---|---|---|
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | Director/Board Member | 2015-02-26 |
ANATARA LIFESCIENCES LTD | Chief Executive Officer | 2015-02-23 |
Q-One Biotech Ltd. | Corporate Officer/Principal | - |
Medeva Plc | Corporate Officer/Principal | - |
IOMAI CORPORATION | Chief Operating Officer | - |
Training of David Venables
University of Surrey | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ANATARA LIFESCIENCES LTD | Health Technology |
Private companies | 6 |
---|---|
Medeva Plc | Health Technology |
Ark Therapeutics Group Plc
Ark Therapeutics Group Plc Miscellaneous Commercial ServicesCommercial Services Ark Therapeutics Group Plc is a gene-based medicine company, which is engaged in the discovery, development and commercialization of products in areas of specialist medicine, with particular focus on vascular disease and cancer. The company was founded by Peter Stephen Keen, John W. Martin, Seppo Ylä-Herttuala, Stephen Barker and Kenneth Powell in July 1997 and is headquartered in London, the United Kingdom. | Commercial Services |
Q-One Biotech Ltd. | Health Technology |
Intercell USA, Inc.
Intercell USA, Inc. BiotechnologyHealth Technology Intercell USA, Inc. discovers and develops vaccines and immune system stimulants. The vaccine patch enhances the efficacy of existing vaccines, enables new vaccines that are viable only through transcutaneous administration and expand the global vaccine market. The company was founded by Gregory M. Glenn and Dean P. Lewis in September 1997 and is headquartered in Gaithersburg, MD. | Health Technology |
Synpromics Ltd.
Synpromics Ltd. Chemicals: SpecialtyProcess Industries Synpromics Ltd. develops and commercializes synthetic promoters to control gene expressions and regulations. The firm is active in cell and gene therapy, biologics bioprocessing, and industrial biotechnology. The company was founded by Michael L. Robert in 2010 and is headquartered in Edinburgh, the United Kingdom. | Process Industries |
Laverock Therapeutics Ltd.
Laverock Therapeutics Ltd. Pharmaceuticals: OtherHealth Technology Laverock Therapeutics Ltd. develops regenerative medicines for hypo immune pancreatic islet cells and oncology therapeutics. The CEO of the British company is David C. Venables. | Health Technology |
- Stock Market
- Insiders
- David Venables